Partnering
towards

New Protein
Therapeutics

Synteny exploits TCR-logic for precision cell-type delivery: three large end-markets

Solid Tumour Oncology
Precise killing of intracellular proteins differentially expressed in tumours

Immune Reset
Cell-specific depletion of populations responsible for autoimmunity

Targeted payload delivery
Precise delivery of payloads to specific, hard-to-target cell types via antigen presentation

We enable partners to access frontier AI in programmable protein therapeutics

Design Sprint
(3 months)

Rapid validation on your priority targets. We deliver AI-designed, lab-validated candidate molecules.

Target ID

Open new biologic frontiers. We help you discover and validate novel targets in your disease areas.

Co-­Development

Share the journey from novel target to clinic. Your disease expertise, our platform capabilities.

License

We are developing a pipeline of first-in-class protein therapeutics for development or licensing.

Platform access
(2026+)

Direct access to our model suite for your discovery programs.